

## Keyword index

### A549 cell

VEGF (vascular endothelial growth factor); Budesonide; Respiratory; Epithelial; Calu-1 cell (Bandi, N. (425) 109)

### Acetylcholine

Anandamide; Fatty acid ethanolamide; 2-Arachidonylglycerol; Glutamate (Stella, N. (425) 189)

### Adenosine

FK506; Adenosine kinase; Endothelial cell (Hwang, K.-K. (425) 85)

### Adenosine kinase

FK506; Adenosine; Endothelial cell (Hwang, K.-K. (425) 85)

### $\beta$ -Adrenoceptor

G protein; Ternary complex; Irreversible complex; G protein–receptor interaction (Onaran, H.O. (425) 181)

### Agonist binding site

5-HT<sub>2A</sub> receptor, rat; 5-HT<sub>2C</sub>1 receptor, rat; Desensitisation; Down-regulation; Up-regulation; Antagonist binding site; Inositol phosphate formation (Van Oekelen, D. (425) 21)

### Allopregnanolone

Picrotoxin-induced seizure; Midazolam; Intra cerebroventricular injection; Dopamine turnover rate; Striatum; (Mouse) (Członkowska, A.I. (425) 121)

### Anandamide

Fatty acid ethanolamide; 2-Arachidonylglycerol; Glutamate; Acetylcholine (Stella, N. (425) 189)

### ANP (Atrial natriuretic peptide)

Antiarrhythmic drug, class Ib; cGMP (Guanosine 3',5'-cyclic monophosphate); Smooth muscle, tracheal (Nakahara, T. (425) 129)

### Antagonist binding site

5-HT<sub>2A</sub> receptor, rat; 5-HT<sub>2C</sub>1 receptor, rat; Desensitisation; Down-regulation; Up-regulation; Agonist binding site; Inositol phosphate formation (Van Oekelen, D. (425) 21)

### Antiarrhythmic

Transient outward current ( $I_{to}$ ); Inward Na<sup>+</sup> current ( $I_{Na}$ ); Hydrogen ion concentration; Open channel blockade; Patch clamp (Franciosi, S. (425) 95)

### Antiarrhythmic drug, class Ib

ANP (Atrial natriuretic peptide); cGMP (Guanosine 3',5'-cyclic monophosphate); Smooth muscle, tracheal (Nakahara, T. (425) 129)

### Antipsychotic

Haloperidol; MS-377; NE-100; Uptake;  $\sigma_1$  receptor (Yamamoto, H. (425) 1)

### Antipsychotic agent

Ziprasidone; Receptor binding, human (Schmidt, A.W. (425) 197)

### Anxiety

Fluvoxamine; Flesinoxan; Conditioned fear stress; 5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor, selective; 5-HT<sub>1A</sub> receptor agonist (Li, X.B. (425) 43)

### 2-Arachidonylglycerol

Anandamide; Fatty acid ethanolamide; Glutamate; Acetylcholine (Stella, N. (425) 189)

### Atherosclerosis

Nitric oxide (NO); Low-density lipoprotein (LDL) oxidation; Superoxide; Endothelial cell; Smooth muscle cell (Jaworski, K. (425) 11)

### ATP

Pelvic nerve; T-1032 (Noto, T. (425) 51)

### Baicalein

Cyclin; Cyclin-dependent kinase; p15<sup>Ink4B</sup>; p53; p21<sup>CIP1/Waf1</sup> (Hsu, S.-L. (425) 165)

### Basophil, human

Nitric oxide (NO); Histamine release; Mast cell; Signal transduction (Peh, K.H. (425) 229)

### Biliary obstruction

Renal oxidative stress; Melatonin (Cruz, A. (425) 135)

### Brain level

5-HT<sub>1B/1D</sub> receptor; 5-HT (5-hydroxytryptamine, serotonin) release; Eletriptan; Zolmitriptan; Sumatriptan; Microdialysis (Johnson, D.E. (425) 203)

### Budesonide

VEGF (vascular endothelial growth factor); Respiratory; Epithelial; Calu-1 cell; A549 cell (Bandi, N. (425) 109)

### Ca<sup>2+</sup>

Doxorubicin; L-Carnitine; Cardioprotection; Cardiotoxicity; Cardiomyocyte (Mijares, A. (425) 117)

### Ca<sup>2+</sup> increase

Endothelin; Neuroblastoma cell; Mitogenesis; Endothelin ET<sub>B</sub> receptor (Kawanabe, Y. (425) 173)

### Calu-1 cell

VEGF (vascular endothelial growth factor); Budesonide; Respiratory; Epithelial; A549 cell (Bandi, N. (425) 109)

### Cardiomyocyte

Ca<sup>2+</sup>; Doxorubicin; L-Carnitine; Cardioprotection; Cardiotoxicity (Mijares, A. (425) 117)

### Cardioprotection

Ca<sup>2+</sup>; Doxorubicin; L-Carnitine; Cardiotoxicity; Cardiomyocyte (Mijares, A. (425) 117)

**Cardiotoxicity**

Ca<sup>2+</sup>; Doxorubicin; L-Carnitine; Cardioprotection; Cardiomyocyte (Mijares, A. (425) 117)

**L-Carnitine**

Ca<sup>2+</sup>; Doxorubicin; Cardioprotection; Cardiotoxicity; Cardiomyocyte (Mijares, A. (425) 117)

**CD11/CD18 activation**

Neutrophil; Zymosan; Phagocytosis; Interleukin-8; PAF (platelet activating factor) (Au, B.-t. (425) 65)

**cGMP (Guanosine 3',5'-cyclic monophosphate)**

Sildenafil; Corpus cavernosum; Diabetes mellitus; Electrical field stimulation (Thompson, C.S. (425) 57)

ANP (Atrial natriuretic peptide); Antiarrhythmic drug, class Ib; Smooth muscle, tracheal (Nakahara, T. (425) 129)

**Codeine**

Morphine; CYP2D2; Opioid dependence; Opioid withdrawal (Chew, M. (425) 159)

**Conditioned fear stress**

Fluvoxamine; Flesinoxan; Anxiety; 5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor, selective; 5-HT<sub>1A</sub> receptor agonist (Li, X.B. (425) 43)

**Corpus cavernosum**

Sildenafil; Diabetes mellitus; Electrical field stimulation; cGMP (Thompson, C.S. (425) 57)

***C. parvum***

HU-210; WIN 55212-2; SR141716A; SR144528; Cytokine; (Mouse) (Smith, S.R. (425) 73)

**Cutaneous vascular hyperpermeability**

Poly-L-arginine; Scratching behavior; Mast cell; Sensory nerve; (Rat) (Hayashi, K.-i. (425) 219)

**Cyclin**

Baicalein; Cyclin-dependent kinase; p15<sup>Ink4B</sup>; p53; p21<sup>CIP1/Waf1</sup> (Hsu, S.-L. (425) 165)

**Cyclin-dependent kinase**

Baicalein; Cyclin; p15<sup>Ink4B</sup>; p53; p21<sup>CIP1/Waf1</sup> (Hsu, S.-L. (425) 165)

**Cyclooxygenase**

Flavonoid; Wogonin; Skin inflammation (Park, B.K. (425) 153)

**CYP2D2**

Codeine; Morphine; Opioid dependence; Opioid withdrawal (Chew, M. (425) 159)

**Cytokine**

HU-210; WIN 55212-2; SR141716A; SR144528; *C. parvum*; (Mouse) (Smith, S.R. (425) 73)

**Desensitisation**

5-HT<sub>2A</sub> receptor, rat; 5-HT<sub>2C</sub> receptor, rat; Down-regulation; Up-regulation; Agonist binding site; Antagonist binding site; Inositol phosphate formation (Van Oekelen, D. (425) 21)

**Diabetes mellitus**

Sildenafil; Corpus cavernosum; Electrical field stimulation; cGMP (Thompson, C.S. (425) 57)

**Dopamine**

Estrogen; Testosterone; Prepulse inhibition; Startle; Glutamate (Van den Buuse, M. (425) 33)

**Dopamine turnover rate**

Picrotoxin-induced seizure; Midazolam; Allopregnanolone; Intra cerebroventricular injection; Striatum; (Mouse) (Członkowska, A.I. (425) 121)

**Down-regulation**

5-HT<sub>2A</sub> receptor, rat; 5-HT<sub>2C</sub> receptor, rat; Desensitisation; Up-regulation; Agonist binding site; Antagonist binding site; Inositol phosphate formation (Van Oekelen, D. (425) 21)

**Doxorubicin**

Ca<sup>2+</sup>; L-Carnitine; Cardioprotection; Cardiotoxicity; Cardiomyocyte (Mijares, A. (425) 117)

**Electrical field stimulation**

Sildenafil; Corpus cavernosum; Diabetes mellitus; cGMP (Thompson, C.S. (425) 57)

**Eletriptan**

5-HT<sub>1B/1D</sub> receptor; 5-HT (5-hydroxytryptamine, serotonin) release; Brain level; Zolmitriptan; Sumatriptan; Microdialysis (Johnson, D.E. (425) 203)

**Endothelial cell**

Atherosclerosis; Nitric oxide (NO); Low-density lipoprotein (LDL) oxidation; Superoxide; Smooth muscle cell (Jaworski, K. (425) 11)

FK506; Adenosine; Adenosine kinase (Hwang, K.-K. (425) 85)

**Endothelin**

Neuroblastoma cell; Ca<sup>2+</sup> increase; Mitogenesis; Endothelin ET<sub>B</sub> receptor (Kawanabe, Y. (425) 173)

**Endothelin ET<sub>B</sub> receptor**

Endothelin; Neuroblastoma cell; Ca<sup>2+</sup> increase; Mitogenesis (Kawanabe, Y. (425) 173)

**Epithelial**

VEGF (vascular endothelial growth factor); Budesonide; Respiratory; Calu-1 cell; A549 cell (Bandi, N. (425) 109)

**Estrogen**

Testosterone; Prepulse inhibition; Startle; Dopamine; Glutamate (Van den Buuse, M. (425) 33)

**Fatty acid ethanolamide**

Anandamide; 2-Arachidonylglycerol; Glutamate; Acetylcholine (Stella, N. (425) 189)

**FK506**

Adenosine; Adenosine kinase; Endothelial cell (Hwang, K.-K. (425) 85)

**Flavonoid**

Wogonin; Cyclooxygenase; Skin inflammation (Park, B.K. (425) 153)

**Flesinoxan**

Fluvoxamine; Anxiety; Conditioned fear stress; 5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor, selective; 5-HT<sub>1A</sub> receptor agonist (Li, X.B. (425) 43)

**Fluvoxamine**

Flesinoxan; Anxiety; Conditioned fear stress; 5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor, selective; 5-HT<sub>1A</sub> receptor agonist (Li, X.B. (425) 43)

**Geissoschizine methyl ether**

5-HT<sub>1A</sub> receptor agonist; 5-HT<sub>2A/2C</sub> receptor antagonist; Head twitch response; Hypothermic response (Pengsuparp, T. (425) 211)

**Glutamate**

Estrogen; Testosterone; Prepulse inhibition; Startle; Dopamine (Van den Buuse, M. (425) 33)

Anandamide; Fatty acid ethanolamide; 2-Arachidonylglycerol; Acetylcholine (Stella, N. (425) 189)

**G protein**

β-Adrenoceptor; Ternary complex; Irreversible complex; G protein–receptor interaction (Onaran, H.O. (425) 181)

**G protein–receptor interaction**

β-Adrenoceptor; G protein; Ternary complex; Irreversible complex (Onaran, H.O. (425) 181)

**Haloperidol**

MS-377; NE-100; Uptake; Antipsychotic; σ<sub>1</sub> receptor (Yamamoto, H. (425) 1)

**Head twitch response**

Geissoschizine methyl ether; 5-HT<sub>1A</sub> receptor agonist; 5-HT<sub>2A/2C</sub> receptor antagonist; Hypothermic response (Pengsuparp, T. (425) 211)

**Histamine release**

Nitric oxide (NO); Mast cell; Basophil, human; Signal transduction (Peh, K.H. (425) 229)

**5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor, selective**  
Fluvoxamine; Flesinoxan; Anxiety; Conditioned fear stress; 5-HT<sub>1A</sub> receptor agonist (Li, X.B. (425) 43)

**5-HT (5-hydroxytryptamine, serotonin) release**

5-HT<sub>1B/1D</sub> receptor; Brain level; Eletriptan; Zolmitriptan; Sumatriptan; Microdialysis (Johnson, D.E. (425) 203)

**5-HT<sub>2C</sub>1 receptor, rat**

5-HT<sub>2A</sub> receptor, rat; Desensitisation; Down-regulation; Up-regulation; Agonist binding site; Antagonist binding site; Inositol phosphate formation (Van Oekelen, D. (425) 21)

**5-HT<sub>1B/1D</sub> receptor**

5-HT (5-hydroxytryptamine, serotonin) release; Brain level; Eletriptan; Zolmitriptan; Sumatriptan; Microdialysis (Johnson, D.E. (425) 203)

**5-HT<sub>1A</sub> receptor agonist**

Fluvoxamine; Flesinoxan; Anxiety; Conditioned fear stress; 5-HT (5-hydroxytryptamine, serotonin) reuptake inhibitor, selective (Li, X.B. (425) 43)

Geissoschizine methyl ether; 5-HT<sub>2A/2C</sub> receptor antagonist; Head twitch response; Hypothermic response (Pengsuparp, T. (425) 211)

**5-HT<sub>2A/2C</sub> receptor antagonist**

Geissoschizine methyl ether; 5-HT<sub>1A</sub> receptor agonist; Head twitch response; Hypothermic response (Pengsuparp, T. (425) 211)

**5-HT<sub>2A</sub> receptor, rat**

5-HT<sub>2C</sub>1 receptor, rat; Desensitisation; Down-regulation; Up-regulation; Agonist binding site; Antagonist binding site; Inositol phosphate formation (Van Oekelen, D. (425) 21)

**HU-210**

WIN 55212-2; SR141716A; SR144528; *C. parvum*; Cytokine; (Mouse) (Smith, S.R. (425) 73)

**Hydrogen ion concentration**

Transient outward current (*I*<sub>to</sub>); Inward Na<sup>+</sup> current (*I*<sub>Na</sub>); Antiarrhythmic; Open channel blockade; Patch clamp (Franciosi, S. (425) 95)

**Hydroxyl radical**

Toxic smoke; Pulmonary edema; Tachykinin; Neutral endopeptidase (Lin, Y.S. (425) 141)

**Hypothermic response**

Geissoschizine methyl ether; 5-HT<sub>1A</sub> receptor agonist; 5-HT<sub>2A/2C</sub> receptor antagonist; Head twitch response (Pengsuparp, T. (425) 211)

**Inositol phosphate formation**

5-HT<sub>2A</sub> receptor, rat; 5-HT<sub>2C</sub>1 receptor, rat; Desensitisation; Down-regulation; Up-regulation; Agonist binding site; Antagonist binding site (Van Oekelen, D. (425) 21)

**Interleukin-8**

Neutrophil; Zymosan; Phagocytosis; PAF (platelet activating factor); CD11/CD18 activation (Au, B.-t. (425) 65)

**Intra cerebroventricular injection**

Picrotoxin-induced seizure; Midazolam; Allopregnanolone; Dopamine turnover rate; Striatum; (Mouse) (Członkowska, A.I. (425) 121)

**Inward Na<sup>+</sup> current (*I*<sub>Na</sub>)**

Transient outward current (*I*<sub>to</sub>); Antiarrhythmic; Hydrogen ion concentration; Open channel blockade; Patch clamp (Franciosi, S. (425) 95)

**Irreversible complex**

β-Adrenoceptor; G protein; Ternary complex; G protein–receptor interaction (Onaran, H.O. (425) 181)

**Low-density lipoprotein (LDL) oxidation**

Atherosclerosis; Nitric oxide (NO); Superoxide; Endothelial cell; Smooth muscle cell (Jaworski, K. (425) 11)

**Mast cell**

Poly-L-arginine; Cutaneous vascular hyperpermeability; Scratching behavior; Sensory nerve; (Rat) (Hayashi, K.-i. (425) 219)

Nitric oxide (NO); Histamine release; Basophil, human; Signal transduction (Peh, K.H. (425) 229)

**Melatonin**

Biliary obstruction; Renal oxidative stress (Cruz, A. (425) 135)

**Meningitis**

Oxidative stress; Peroxynitrite; Uric acid (Kastenbauer, S. (425) 149)

**Microdialysis**

5-HT<sub>1B/1D</sub> receptor; 5-HT (5-hydroxytryptamine, serotonin) release; Brain level; Eletriptan; Zolmitriptan; Sumatriptan (Johnson, D.E. (425) 203)

**Midazolam**

Picrotoxin-induced seizure; Allopregnanolone; Intra cerebroventricular injection; Dopamine turnover rate; Striatum; (Mouse) (Członkowska, A.I. (425) 121)

**Mitogenesis**

Endothelin; Neuroblastoma cell; Ca<sup>2+</sup> increase; Endothelin ET<sub>B</sub> receptor (Kawanabe, Y. (425) 173)

**Morphine**

Codeine; CYP2D2; Opioid dependence; Opioid withdrawal (Chew, M. (425) 159)

**MS-377**

Haloperidol; NE-100; Uptake; Antipsychotic;  $\sigma_1$  receptor (Yamamoto, H. (425) 1)

**NE-100**

Haloperidol; MS-377; Uptake; Antipsychotic;  $\sigma_1$  receptor (Yamamoto, H. (425) 1)

**Neuroblastoma cell**

Endothelin;  $\text{Ca}^{2+}$  increase; Mitogenesis; Endothelin  $\text{ET}_B$  receptor (Kawanabe, Y. (425) 173)

**Neurokinin B**

Uterus; (Rat) (Pinto, F.M. (425) R1)

**Neutral endopeptidase**

Toxic smoke; Pulmonary edema; Tachykinin; Hydroxyl radical (Lin, Y.S. (425) 141)

**Neutrophil**

Zymosan; Phagocytosis; Interleukin-8; PAF (platelet activating factor); CD11/CD18 activation (Au, B.-t. (425) 65)

**Nitric oxide (NO)**

Atherosclerosis; Low-density lipoprotein (LDL) oxidation; Superoxide; Endothelial cell; Smooth muscle cell (Jaworski, K. (425) 11)

Histamine release; Mast cell; Basophil, human; Signal transduction (Peh, K.H. (425) 229)

**Open channel blockade**

Transient outward current ( $I_{to}$ ); Inward  $\text{Na}^+$  current ( $I_{Na}$ ); Antiarrhythmic; Hydrogen ion concentration; Patch clamp (Franciosi, S. (425) 95)

**Opioid dependence**

Codeine; Morphine; CYP2D2; Opioid withdrawal (Chew, M. (425) 159)

**Opioid withdrawal**

Codeine; Morphine; CYP2D2; Opioid dependence (Chew, M. (425) 159)

**Oxidative stress**

Meningitis; Peroxynitrite; Uric acid (Kastenbauer, S. (425) 149)

**p15<sup>Ink4B</sup>**

Baicalein; Cyclin; Cyclin-dependent kinase; p53; p21<sup>CIP1/Waf1</sup> (Hsu, S.-L. (425) 165)

**p21<sup>CIP1/Waf1</sup>**

Baicalein; Cyclin; Cyclin-dependent kinase; p15<sup>Ink4B</sup>; p53 (Hsu, S.-L. (425) 165)

**p53**

Baicalein; Cyclin; Cyclin-dependent kinase; p15<sup>Ink4B</sup>; p21<sup>CIP1/Waf1</sup> (Hsu, S.-L. (425) 165)

**PAF (platelet activating factor)**

Neutrophil; Zymosan; Phagocytosis; Interleukin-8; CD11/CD18 activation (Au, B.-t. (425) 65)

**Patch clamp**

Transient outward current ( $I_{to}$ ); Inward  $\text{Na}^+$  current ( $I_{Na}$ ); Antiarrhythmic; Hydrogen ion concentration; Open channel blockade (Franciosi, S. (425) 95)

**Pelvic nerve**

ATP; T-1032 (Noto, T. (425) 51)

**Peroxynitrite**

Meningitis; Oxidative stress; Uric acid (Kastenbauer, S. (425) 149)

**Phagocytosis**

Neutrophil; Zymosan; Interleukin-8; PAF (platelet activating factor); CD11/CD18 activation (Au, B.-t. (425) 65)

**Picrotoxin-induced seizure**

Midazolam; Allopregnanolone; Intra cerebroventricular injection; Dopamine turnover rate; Striatum; (Mouse) (Członkowska, A.I. (425) 121)

**Poly-L-arginine**

Cutaneous vascular hyperpermeability; Scratching behavior; Mast cell; Sensory nerve; (Rat) (Hayashi, K.-i. (425) 219)

**Prepulse inhibition**

Estrogen; Testosterone; Startle; Dopamine; Glutamate (Van den Buuse, M. (425) 33)

**Pulmonary edema**

Toxic smoke; Tachykinin; Hydroxyl radical; Neutral endopeptidase (Lin, Y.S. (425) 141)

**Receptor binding, human**

Antipsychotic agent; Ziprasidone (Schmidt, A.W. (425) 197)

**Renal oxidative stress**

Biliary obstruction; Melatonin (Cruz, A. (425) 135)

**Respiratory**

VEGF (vascular endothelial growth factor); Budesonide; Epithelial; Calu-1 cell; A549 cell (Bandi, N. (425) 109)

**Scratching behavior**

Poly-L-arginine; Cutaneous vascular hyperpermeability; Mast cell; Sensory nerve; (Rat) (Hayashi, K.-i. (425) 219)

**Sensory nerve**

Poly-L-arginine; Cutaneous vascular hyperpermeability; Scratching behavior; Mast cell; (Rat) (Hayashi, K.-i. (425) 219)

**Signal transduction**

Nitric oxide (NO); Histamine release; Mast cell; Basophil, human (Peh, K.H. (425) 229)

**Sildenafil**

Corpus cavernosum; Diabetes mellitus; Electrical field stimulation; cGMP (Thompson, C.S. (425) 57)

**Skin inflammation**

Flavonoid; Wogonin; Cyclooxygenase (Park, B.K. (425) 153)

**Smooth muscle cell**

Atherosclerosis; Nitric oxide (NO); Low-density lipoprotein (LDL) oxidation; Superoxide; Endothelial cell (Jaworski, K. (425) 11)

**Smooth muscle, tracheal**

ANP (Atrial natriuretic peptide); Antiarrhythmic drug, class Ib; cGMP (Guanosine 3',5'-cyclic monophosphate) (Nakahara, T. (425) 129)

**SR144528**

HU-210; WIN 55212-2; SR141716A; *C. parvum*; Cytokine; (Mouse) (Smith, S.R. (425) 73)

**SR141716A**

HU-210; WIN 55212-2; SR144528; *C. parvum*; Cytokine; (Mouse) (Smith, S.R. (425) 73)

**$\sigma_1$  receptor**

Haloperidol; MS-377; NE-100; Uptake; Antipsychotic (Yamamoto, H. (425) 1)

**Startle**

Estrogen; Testosterone; Prepulse inhibition; Dopamine; Glutamate (Van den Buuse, M. (425) 33)

**Striatum**

Picrotoxin-induced seizure; Midazolam; Allopregnanolone; Intra cerebroventricular injection; Dopamine turnover rate; (Mouse) (Członkowska, A.I. (425) 121)

**Sumatriptan**

5-HT<sub>1B/1D</sub> receptor; 5-HT (5-hydroxytryptamine, serotonin) release; Brain level; Eletriptan; Zolmitriptan; Microdialysis (Johnson, D.E. (425) 203)

**Superoxide**

Atherosclerosis; Nitric oxide (NO); Low-density lipoprotein (LDL) oxidation; Endothelial cell; Smooth muscle cell (Jaworski, K. (425) 11)

**T-1032**

ATP; Pelvic nerve (Noto, T. (425) 51)

**Tachykinin**

Toxic smoke; Pulmonary edema; Hydroxyl radical; Neutral endopeptidase (Lin, Y.S. (425) 141)

**Ternary complex**

$\beta$ -Adrenoceptor; G protein; Irreversible complex; G protein–receptor interaction (Onaran, H.O. (425) 181)

**Testosterone**

Estrogen; Prepulse inhibition; Startle; Dopamine; Glutamate (Van den Buuse, M. (425) 33)

**Toxic smoke**

Pulmonary edema; Tachykinin; Hydroxyl radical; Neutral endopeptidase (Lin, Y.S. (425) 141)

**Transient outward current ( $I_{to}$ )**

Inward Na<sup>+</sup> current ( $I_{Na}$ ); Antiarrhythmic; Hydrogen ion concentration; Open channel blockade; Patch clamp (Franciosi, S. (425) 95)

**Up-regulation**

5-HT<sub>2A</sub> receptor, rat; 5-HT<sub>2C</sub>1 receptor, rat; Desensitisation; Down-regulation; Agonist binding site; Antagonist binding site; Inositol phosphate formation (Van Oekelen, D. (425) 21)

**Uptake**

Haloperidol; MS-377; NE-100; Antipsychotic;  $\sigma_1$  receptor (Yamamoto, H. (425) 1)

**Uric acid**

Meningitis; Oxidative stress; Peroxynitrite (Kastenbauer, S. (425) 149)

**Uterus**

Neurokinin B; (Rat) (Pinto, F.M. (425) R1)

**VEGF (vascular endothelial growth factor)**

Budesonide; Respiratory; Epithelial; Calu-1 cell; A549 cell (Bandi, N. (425) 109)

**WIN 55212-2**

HU-210; SR141716A; SR144528; *C. parvum*; Cytokine; (Mouse) (Smith, S.R. (425) 73)

**Wogonin**

Flavonoid; Cyclooxygenase; Skin inflammation (Park, B.K. (425) 153)

**Ziprasidone**

Antipsychotic agent; Receptor binding, human (Schmidt, A.W. (425) 197)

**Zolmitriptan**

5-HT<sub>1B/1D</sub> receptor; 5-HT (5-hydroxytryptamine, serotonin) release; Brain level; Eletriptan; Sumatriptan; Microdialysis (Johnson, D.E. (425) 203)

**Zymosan**

Neutrophil; Phagocytosis; Interleukin-8; PAF (platelet activating factor); CD11/CD18 activation (Au, B.-t. (425) 65)